CAR-T is under clinical development by Anixa Biosciences and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene therapy is under development for the treatment of epithelial ovarian cancer, breast cancer, peritoneal cancer and fallopian tube cancer. The therapy comprises of chimeric antigen receptor T-cells which act by targeting cells expressing follicle stimulating hormone receptor (FSHR).
Anixa Biosciences overview
Anixa Biosciences (Anixa) is a biotechnology company. The company develops and acquires patented technologies in the areas such as cancer diagnostics, encrypted communications and semiconductor fabrication. It also develops non-invasive blood tests for the early detection of solid tumor-based cancers. The company primarily focuses on developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs and a COVID-19 therapeutics program on inhibiting certain viral protein functions. Anixa’s key therapeutics programs includes breast cancer and ovarian cancer. It also involves in examining emerging technologies in complementary fields for future development and commercialization. Anixa is headquartered in San Jose, California, the US.
For a complete picture of CAR-T’s drug-specific PTSR and LoA scores, buy the report here.